| aldactone vs furosemide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| hospitalisation for cardiovascular causes | no data | | death from cardiovascular causes or hospitalization for cardiovascular causes | no data | | serious hyperkalemia | no data | | Sudden death | no data | | death from cardiovascular causes or hospitalization for heart failure | no data | | Death from any cause or hospitalization for any reason | no data | | exacerbation of heart failure | no data | | NYHA class improvement | no data | | Death from any cause or hospitalization for heart failure | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | no data | | All cause death | no data | | Hospitalization for any reason | no data | | Adverse events leading to treatment discontinuation | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| furosemide + spironolactone vs prenalterol | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| hospitalisation for cardiovascular causes | no data | | death from cardiovascular causes or hospitalization for cardiovascular causes | no data | | serious hyperkalemia | no data | | Sudden death | no data | | death from cardiovascular causes or hospitalization for heart failure | no data | | Death from any cause or hospitalization for any reason | no data | | exacerbation of heart failure | no data | | NYHA class improvement | 0.75 [0.10 5.54] | p=1.00 | 0 | 20 | 1 | Dalhstrom, | | Death from any cause or hospitalization for heart failure | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | no data | | All cause death | no data | | Hospitalization for any reason | no data | | Adverse events leading to treatment discontinuation | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| spironolactone vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| hospitalisation for cardiovascular causes | no data | | death from cardiovascular causes or hospitalization for cardiovascular causes | no data | | serious hyperkalemia | no data | | Sudden death | no data | | death from cardiovascular causes or hospitalization for heart failure | no data | | Death from any cause or hospitalization for any reason | no data | | exacerbation of heart failure | no data | | NYHA class improvement | no data | | Death from any cause or hospitalization for heart failure | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | no data | | All cause death | no data | | Hospitalization for any reason | no data | | Adverse events leading to treatment discontinuation | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| spironolactone vs placebo | No demonstrated result Adverse events leading to treatment discontinuation by 59% (harmful effect) suggested hospitalisation for cardiovascular causes by 21% (not demonstrated) suggested exacerbation of heart failure by 21% (not demonstrated) suggested NYHA class improvement by 24% (not demonstrated) suggested Cardiovascular death by 26% (not demonstrated) suggested All cause death by 25% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| hospitalisation for cardiovascular causes | 0.79 [0.65 0.97] | p=0.04 | 0 | 1663 | 1 | RALES, | | death from cardiovascular causes or hospitalization for cardiovascular causes | no data | | serious hyperkalemia | 2.05 [0.19 22.61] | p=1.00 | 0 | 1663 | 1 | RALES, | | Sudden death | 0.76 [0.56 1.03] | p=1.00 | 0 | 1663 | 1 | RALES, | | death from cardiovascular causes or hospitalization for heart failure | no data | | Death from any cause or hospitalization for any reason | no data | | exacerbation of heart failure | 0.79 [0.65 0.96] | p=0.04 | 0 | 1663 | 1 | RALES, | | NYHA class improvement | 1.24 [1.02 1.51] | p=0.04 | 0 | 1663 | 1 | RALES, | | Death from any cause or hospitalization for heart failure | no data | | Cardiovascular death | 0.74 [0.61 0.91] | p=0.04 | 0 | 1663 | 1 | RALES, | | hospitalisation for heart failure | no data | | All cause death | 0.75 [0.62 0.92] | p=0.04 | 0 | 1663 | 1 | RALES, | | Hospitalization for any reason | no data | | Adverse events leading to treatment discontinuation | 1.59 [1.05 2.39] | p=0.04 | 0 | 1663 | 1 | RALES, | | Adverse events | 1.03 [0.81 1.32] | p=1.00 | 0 | 1663 | 1 | RALES, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| spironolactone+captopril vs captopril | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| hospitalisation for cardiovascular causes | no data | | death from cardiovascular causes or hospitalization for cardiovascular causes | no data | | serious hyperkalemia | no data | | Sudden death | no data | | death from cardiovascular causes or hospitalization for heart failure | no data | | Death from any cause or hospitalization for any reason | no data | | exacerbation of heart failure | no data | | NYHA class improvement | no data | | Death from any cause or hospitalization for heart failure | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | no data | | All cause death | no data | | Hospitalization for any reason | no data | | Adverse events leading to treatment discontinuation | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| spironolactone+furosemide vs spironolactone+butizide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| hospitalisation for cardiovascular causes | no data | | death from cardiovascular causes or hospitalization for cardiovascular causes | no data | | serious hyperkalemia | no data | | Sudden death | no data | | death from cardiovascular causes or hospitalization for heart failure | no data | | Death from any cause or hospitalization for any reason | no data | | exacerbation of heart failure | no data | | NYHA class improvement | no data | | Death from any cause or hospitalization for heart failure | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | no data | | All cause death | no data | | Hospitalization for any reason | no data | | Adverse events leading to treatment discontinuation | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
